Login to Your Account



Other News To Note


Tuesday, February 14, 2012

• Amarin Corp. plc, of Dublin, Ireland, said it was notified by the FDA that no advisory meeting will be scheduled in connection with the new drug application for AMR101 (icosapent ethyl), a prescription-grade omega-3 fatty acid, for use in patients with very high triglycerides (less than or equal to 500 mg/dL). The agency has set a PDUFA date of July 26.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription